Moreover, this ratio has increased to one-third for drugs given a priority review. Because we do have specific evidence for interactions between some medications and grapefruit, the public should be updated about new drugs where this interaction may be missed.
Is it sufficient that we identify these warnings and withdrawals only after they may have caused human suffering? After 20 years and hundreds of research publications on the topic of grapefruitdrug interaction, is there not enough well-documented science to predict with high likelihood the adverse effects and toxicity before unnecessary exposure? Our considered contention is that this is indeed the case. Moreover, a recent editorial in BMJ has lent further credence to the relevance of our conclusions. 4 Even if the incidence of serious toxicity from a grapefruit-drug interaction was low in the patient population, which is as yet not fully known, the consequences would be dire (yet easily prevented). Moreover, why would you knowingly or even theoretically put yourself or others in harm's way? Caution is by far the wisest approach.
Pregnancy and isotretinoin therapy
We read with interest the article by Choi and colleagues on isotretinoin therapy and the importance of a multilevel approach to ensure adequate contraception in women taking potentially teratogenic medications. 1 We agree that it is essential that health care providers know the failure rates of various contraceptive methods when counselling patients. However, we encourage health care providers to become familiar with the more recent and accepted perfect and typical use failure rates reported by Trussell and colleagues in Appendix 1, available at www.cmaj.ca /lookup /suppl /doi:10.1503 /cmaj .1132111 /-/DC1, 2 which in some instances are quite different than the ones the cited by Choi and colleagues. 3 The rates reported by Trussell and colleagues are referred to in numerous contraception guidelines including those from the Society of Obstetricians and Gynaecologists of Canada, 4 the Centers for Disease Control and Prevention, 5 and the World Health Organization. 6 Prescribers must also understand the difference between perfect-use and typical-use failure rates. Failure rates are reported as the percentage of women who will have an unintended pregnancy during the first year of use of a method. Perfect use may be hard to achieve, particularly with more compliance-demanding methods, which explains why typical-use failure rates are much higher than perfect -use failure rates with methods such as condoms and oral contraceptives. Longacting reversible contraceptive methods such as intrauterine contraceptive devices and implants are not as reliant on user compliance and hence typical-use failure rates approach those of perfect-use rates. Long-acting reversible contraceptives also have lower discontinuation rates at one year. 2 We encourage contraceptive prescribers to be familiar with Trussell's reported failure rates, 2 and reiterate that women of reproductive age who use teratogenic medications should be counselled about all contraceptive options -particularly long-acting reversible contraceptives given their low typical-and perfect-use failure rates and their increased adherence. 
